1. Factitious hypoglycemia in insulin-treated diabetic patients.
- Author
-
Galvez T, Lotierzo M, Conquet G, Verani Q, Aguilhon C, Raingeard I, Cristol JP, and Renard E
- Subjects
- Humans, Insulin adverse effects, C-Peptide adverse effects, Hypoglycemia chemically induced, Hypoglycemia diagnosis, Factitious Disorders diagnosis, Factitious Disorders chemically induced, Factitious Disorders complications, Pancreatic Neoplasms complications, Diabetes Mellitus drug therapy, Diabetes Mellitus chemically induced
- Abstract
Factitious hypoglycemia is a factitious disorder according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), referring to intentionally covertly induced hypoglycemia, with potentially severe consequences. Knowledge of factitious hypoglycemia relies on case reports, and evidence-based information and guidelines are lacking. Diagnosing factitious hypoglycemia in insulin-treated diabetic persons is therefore challenging and often requires a long and costly process. Moreover, the typical metrics proposed to differentiate insulin-induced factitious hypoglycemia from insulinoma (i.e., high insulin and low C-peptide versus high insulin and high C-peptide, respectively) are not always applicable, depending on whether the insulin quantification method can detect the insulin analog. When factitious hypoglycemia is suspected, an emerging trend from recent publications advocates a combination of two insulin quantification methods with different cross-reactivity for insulin analogs, early on in the diagnostic process., (Copyright © 2023 Elsevier Masson SAS. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF